Neurological applications of products in cellular therapy and preclinical, clinical and approved stages

Cellular therapeutics with neurology applications currently encompass the entire range of development from preclinicals to approved, commercially available products in use.

See the specific selected neurology cell therapy products on the market or in development by companies in the market:

  • Personalized stem cell therapies for tissue regeneration
  • Cell treatment for amyotropic lateral sclerosis
  • Biopharmaceutical for stroke
  • MultiStem for attentional/cognitive areas; MultiStem Stroke
  • Cellular (embrionic stem cell) implants for the regeneration of damaged or sick neural tissue
  • Stem cells for neurodegenerative diseases
  • Autologous cell-based therapies for neurosurgical applications
  • Neural progenitor cells
  • Biopharmaceuticals for chronic regenerative disorders, including spinal cord injury (glial cells)
  • Biotech diagnostic assays for neurodegeneration and other applications
  • Regenerative implants for neurosurgical applications
  • Neurotrophin cellular therapy for Parkinson’s disease, Alzheimer’s disease, Huntington’s disease and stroke
  • Stem cell-based therapies for neurological and other applications
  • Human neural stem cell transplantation
  • Neural stem therapies for patients with neurological diseases such as Parkinson’s, Alzheimer's, epilepsy, spinal cord injury, stroke and multiple sclerosis and amyotropic lateral sclerosis
  • Biotherapeutics for amyotropic lateral sclerosis and Parkinson’s
  • Bioregeneration matrix
  • Stem cell therapies for neurological applications (multiple sclerosis, stroke)
  • Bioresorbable nerve guide
  • Cellular therapy for spinal cord injury
  • Neurological cell growth and function
  • Stem cell therapy for disabled stroke victims
  • Plans to develop and commercialize products for Parkinson's, spinal cord injury, and other diseases
  • Stem cell-based biopharm for neurodegenerative and other diseases
  • Cell-based technologies for CNS and liverHuCNS-SC (purified human neural stem cells) for neurodegenerative disorders
  • Therapeutics for neurodegenerative diseases
  • Dura substitute for repair of cranial dura mater, spinal dura mater (marketed by Medtronic)
  • Biopharmaceutical for Alzheimer's
  • Stem cells created from adult cells (retrodifferentiation technology) possibly to be developed for spinal cord injury applications

The global market for neurological applications of cellular and tissue engineered therapeutic products is currently under $300 million, but is on pace to near $1 billion by 2018. (See MedMarket Diligence report #S520.)